Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City Veterans Administration Medical Center, Iowa City, IA 52442, USA.
Cancer J. 2010 Mar-Apr;16(2):125-31. doi: 10.1097/PPO.0b013e3181d823c8.
Colorectal cancer metastatic to the liver is a common oncologic problem, and carefully selected patients can be successfully treated with surgical resection of liver metastases. Perioperative chemotherapy has been shown to increase progression-free survival in patients with resectable liver metastases and can currently be considered a standard therapy for eligible patients. Preoperative chemotherapy can downstage unresectable liver metastases and allow a complete resection. More aggressive chemotherapy as well has the incorporation of targeted agents such as cetuximab and bevacizumab into modern chemotherapy regimens has resulted in higher response rates, which may translate into improved survival. Preoperative chemotherapy can increase postoperative complications after hepatic resection, and the decision to use such therapy should be made in a multidisciplinary setting.
结直肠癌肝转移是一种常见的肿瘤学问题，精心选择的患者可以通过手术切除肝转移灶获得成功治疗。围手术期化疗已被证明可以增加可切除肝转移灶患者的无进展生存期，目前可被视为符合条件患者的标准治疗方法。术前化疗可以使不可切除的肝转移灶降期，并使完全切除成为可能。更积极的化疗以及将西妥昔单抗和贝伐珠单抗等靶向药物纳入现代化疗方案，已导致更高的缓解率，这可能转化为改善的生存。术前化疗会增加肝切除术后的并发症，因此应在多学科环境下做出使用此类治疗的决策。
